Home » Stocks » ORMP » Company

Oramed Pharmaceuticals Inc. (ORMP)

Stock Price: $13.86 USD 0.38 (2.82%)
Updated Jun 22, 2021 4:00 PM EDT - Market closed
Oramed Pharmaceuticals Inc.
Country United States
Founded 2002
Industry Biotechnology
Sector Healthcare
CEO Nadav Kidron

Contact Details

Address:1185 Avenue Of The Americas, 3Rd Floor
New York, New York 10036
United States
Phone 844 967 2633

Stock Information

Ticker Symbol ORMP
Exchange NASDAQ
Fiscal Year September - August
Reporting Currency US Dollars
CIK Code 0001176309
CUSIP Number 68403P104
ISIN Number US68403P2039
Employer ID 98-0376008

Company Description

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides.

Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes.

It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule.

The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.

Key Executives

Nadav KidronPresident, Chief Executive Officer and Executive Director
Avraham GabayChief Financial Officer, Treasurer and Secretary
Joshua HexterChief Operating and Business Officer
Dr. Miriam KidronChief Scientific Officer and Director
Dr. Roy Eldor M.D., Ph.D.Chief Medical Advisor and Member of the Scientific Advisory Board